Outcome and relapse risks of thrombotic thrombocytopaenic purpura: An Egyptian experience

Postgraduate Medical Journal

Volumn 88, Issue 1042, 2012, Pages 433-436

  El Husseiny, Noha M ^a   Goubran, Hady ^b   Fahmy, Hala M ^a   Tawfik, Nehad M ^a   Moustafa, Heba ^a   Amin, Sherif N ^a   El Ekiaby, Magdy ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Saskatoon Cancer Center   (Canada)

^c Shabrawishy Hospital   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; LACTATE DEHYDROGENASE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE DURATION; EGYPT; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMAPHERESIS; RELAPSE; REMISSION; RISK FACTOR; SPLENECTOMY; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; COHORT STUDIES; EGYPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RISK FACTORS; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84864100622     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-130375     Document Type: Article

References (24)

1. James WD, Berger TG, et al. Andrews' Diseases of the Skin: Clinical Dermatology. London: Saunders Elsevier, 2006.
2. Thrombotic Thrombocytopenic Purpura at Dorland's Medical Dictionary. 32nd edition. Edited by William Alexander Newman Dorland. Elsevier, London.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589e600.
4. Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thromboticmicroangiopathies. Best Pract Res Clin Haematol 2009;22:567e76.
5. Moake JL. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004;41:4e14.
6. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-1 assays thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:631e40.
7. Sadler JE, Moake JL, Toshiyuki M, et al. Recent advances in thrombotic thrombocytopenic purpura. American Society of Hematology Education Program 2004:407e23.
8. Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500e11.
9. Verbeke L, Delforge M, Dierickx D. Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2010;21:3e10.
10. Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001;86:844e50.
11. Zhan H, Streiff MB, King KE, et al. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 2010;50: 868e74.
12. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010;47:170e9.
13. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpuraehemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;101: 60e8.
14. Tuncer HH, Oster RA, Huang ST, et al. Predictors response relapse a cohort adults thrombotic thrombocytopenic purpuraehemolytic uremic syndrome: a single-institution experience. Transfusion 2007;47: 107e14.
15. Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience 4 cases. Ann Hematol 2000;79:66e72.
16. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore). 1981;60:413e28.
17. Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura. Am J Med 1987;83:437e44.
18. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393e7.
19. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010;107:14757e62.
20. Ramanan AS, Thirumala S, Chandrasekaran VJ. Thrombotic thrombocytopenia purpura: a single institution experience. Clin Apher 1999;14:9e13.
21. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis factors predicting response plasma exchange. Ann Hematol 1995;70:319e23.
22. Alvarez-Larrán A, del Río-Garma J, Pujol M, et al. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison presenting clinical characteristics response treatment. Ann Hematol 2009;88:973e8.
23. Hwang WY, Chai LYA, Ng HJ, et al. Therapeutic plasmapheresis for the treatment of the thrombotic thrombocytopenic purpuraehaemolytic uraemic syndromes. Sungapore Med J 2004;45:219e23.
24. Dubois L, Gray DK. Splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg 2010;53:349e55.